OBJECTIVE: HLA class I polymorphism is known to affect the rate of progression to AIDS after infection with HIV-1. Here we test the consistency of HLA-B allelic effects on progression to AIDS, heterosexual HIV transmission, and 'set point' viral levels. METHODS: We used adjusted Cox proportional hazard models in previously published relative hazard values for the effect of HLA-B alleles on progression to AIDS (n = 1089). The transmission study included 303 HIV-1-infected men with hemophilia and their 323 female sex partners (Multicenter Hemophilia Cohort Study cohort). Among 259 HIV-1 seroconverters (Multicenter AIDS Cohort Study cohort), HIV RNA levels at 'set point' were determined in stored plasma samples by a reverse-transcription polymerase chain reaction assay. HLA-B genotyping was performed by sequence-specific oligonucleotide hybridization and DNA sequencing. RESULTS: Several HLA-B alleles showed consistent associations for AIDS risk, infectivity, and 'set point' HIV RNA. HLA-B*35 was associated with more rapid progression to AIDS (relative hazard 1.39; P = 0.008), greater infectivity (odds ratio 3.14; P = 0.002), and higher HIV RNA (P = 0.01), whereas the presence of either B*27 or B*57 associated with slower progression to AIDS (B*27: relative hazard 0.49, P < 0.001; B*57: relative hazard 0.40, P < 0.0001), less infectivity (odds ratio 0.22 and 0.31, respectively, though not significant), and lower viral levels (P < 0.0001). Importantly, HLA-B polymorphism in female partners was not associated with susceptibility to HIV-1 infection. CONCLUSION: HLA-B polymorphisms that affect the risk of AIDS may also alter HIV-1 infectivity, probably through the common mechanism of viral control, but they do not appear to protect against infection in our cohort.
OBJECTIVE: HLA class I polymorphism is known to affect the rate of progression to AIDS after infection with HIV-1. Here we test the consistency of HLA-B allelic effects on progression to AIDS, heterosexual HIV transmission, and 'set point' viral levels. METHODS: We used adjusted Cox proportional hazard models in previously published relative hazard values for the effect of HLA-B alleles on progression to AIDS (n = 1089). The transmission study included 303 HIV-1-infectedmen with hemophilia and their 323 female sex partners (Multicenter Hemophilia Cohort Study cohort). Among 259 HIV-1 seroconverters (Multicenter AIDS Cohort Study cohort), HIV RNA levels at 'set point' were determined in stored plasma samples by a reverse-transcription polymerase chain reaction assay. HLA-B genotyping was performed by sequence-specific oligonucleotide hybridization and DNA sequencing. RESULTS: Several HLA-B alleles showed consistent associations for AIDS risk, infectivity, and 'set point' HIV RNA. HLA-B*35 was associated with more rapid progression to AIDS (relative hazard 1.39; P = 0.008), greater infectivity (odds ratio 3.14; P = 0.002), and higher HIV RNA (P = 0.01), whereas the presence of either B*27 or B*57 associated with slower progression to AIDS (B*27: relative hazard 0.49, P < 0.001; B*57: relative hazard 0.40, P < 0.0001), less infectivity (odds ratio 0.22 and 0.31, respectively, though not significant), and lower viral levels (P < 0.0001). Importantly, HLA-B polymorphism in female partners was not associated with susceptibility to HIV-1 infection. CONCLUSION:HLA-B polymorphisms that affect the risk of AIDS may also alter HIV-1 infectivity, probably through the common mechanism of viral control, but they do not appear to protect against infection in our cohort.
Authors: Marcus Altfeld; Marylyn M Addo; Eric S Rosenberg; Frederick M Hecht; Paul K Lee; Martin Vogel; Xu G Yu; Rika Draenert; Mary N Johnston; Daryld Strick; Todd M Allen; Margaret E Feeney; James O Kahn; Rafick P Sekaly; Jay A Levy; Jürgen K Rockstroh; Philip J Goulder; Bruce D Walker Journal: AIDS Date: 2003-12-05 Impact factor: 4.177
Authors: Xiaojiang Gao; Arman Bashirova; Astrid K N Iversen; John Phair; James J Goedert; Susan Buchbinder; Keith Hoots; David Vlahov; Marcus Altfeld; Stephen J O'Brien; Mary Carrington Journal: Nat Med Date: 2005-11-20 Impact factor: 53.440
Authors: Tania M Welzel; Xiaojiang Gao; Ruth M Pfeiffer; Maureen P Martin; Stephen J O'Brien; James J Goedert; Mary Carrington; Thomas R O'Brien Journal: AIDS Date: 2007-01-11 Impact factor: 4.177
Authors: Geraldine M A Gillespie; Rupert Kaul; Tao Dong; Hong-Bing Yang; Tim Rostron; Job J Bwayo; Peter Kiama; Tim Peto; Francis A Plummer; Andrew J McMichael; Sarah L Rowland-Jones Journal: AIDS Date: 2002-05-03 Impact factor: 4.177
Authors: Benigno Rodríguez; Ajay K Sethi; Vinay K Cheruvu; Wilma Mackay; Ronald J Bosch; Mari Kitahata; Stephen L Boswell; W Christopher Mathews; David R Bangsberg; Jeffrey Martin; Christopher C Whalen; Scott Sieg; Suhrida Yadavalli; Steven G Deeks; Michael M Lederman Journal: JAMA Date: 2006-09-27 Impact factor: 56.272
Authors: Robert Winchester; Jane Pitt; Manhattan Charurat; Laurence S Magder; Harald H H Göring; Alan Landay; Jennifer S Read; William Shearer; Edward Handelsman; Katherine Luzuriaga; George V Hillyer; William Blattner Journal: J Acquir Immune Defic Syndr Date: 2004-06-01 Impact factor: 3.731
Authors: Jacques Fellay; Kevin V Shianna; Dongliang Ge; Sara Colombo; Bruno Ledergerber; Mike Weale; Kunlin Zhang; Curtis Gumbs; Antonella Castagna; Andrea Cossarizza; Alessandro Cozzi-Lepri; Andrea De Luca; Philippa Easterbrook; Patrick Francioli; Simon Mallal; Javier Martinez-Picado; José M Miro; Niels Obel; Jason P Smith; Josiane Wyniger; Patrick Descombes; Stylianos E Antonarakis; Norman L Letvin; Andrew J McMichael; Barton F Haynes; Amalio Telenti; David B Goldstein Journal: Science Date: 2007-07-19 Impact factor: 47.728
Authors: Iris Chen; Vanessa Cummings; Jessica M Fogel; Mark A Marzinke; William Clarke; Matthew B Connor; Sam Griffith; Susan Buchbinder; Steven Shoptaw; Carlos Del Rio; Manya Magnus; Sharon Mannheimer; Darrell P Wheeler; Kenneth H Mayer; Beryl A Koblin; Susan H Eshleman Journal: J Acquir Immune Defic Syndr Date: 2014-12-01 Impact factor: 3.731
Authors: D R Chopera; M Mlotshwa; Z Woodman; K Mlisana; D de Assis Rosa; D P Martin; S Abdool Karim; C M Gray; C Williamson Journal: J Virol Date: 2011-05-25 Impact factor: 5.103
Authors: Heather A Prentice; Matthew A Price; Travis R Porter; Emmanuel Cormier; Michael J Mugavero; Anatoli Kamali; Etienne Karita; Shabir Lakhi; Eduard J Sanders; Omu Anzala; Pauli N Amornkul; Susan Allen; Eric Hunter; Richard A Kaslow; Jill Gilmour; Jianming Tang Journal: Virology Date: 2013-12-12 Impact factor: 3.616
Authors: Sarita D Boyd; Frank Maldarelli; Irini Sereti; G Laissa Ouedraogo; Catherine A Rehm; Valerie Boltz; Diana Shoemaker; Alice K Pau Journal: Antivir Ther Date: 2011
Authors: Jianming Tang; Emmanuel Cormier; Jill Gilmour; Matthew A Price; Heather A Prentice; Wei Song; Anatoli Kamali; Etienne Karita; Shabir Lakhi; Eduard J Sanders; Omu Anzala; Pauli N Amornkul; Susan Allen; Eric Hunter; Richard A Kaslow Journal: J Virol Date: 2011-06-29 Impact factor: 5.103
Authors: Nicolas Vince; Arman A Bashirova; Alexandra Lied; Xiaojiang Gao; Lucy Dorrell; Paul J McLaren; Jacques Fellay; Mary Carrington Journal: J Infect Dis Date: 2014-04-08 Impact factor: 5.226
Authors: Rajesh T Gandhi; Ronald J Bosch; Ram Rangsin; Thippawan Chuenchitra; Narongrid Sirisopana; Jerome H Kim; Merlin L Robb; Sasijit Vejbaesya; Robert M Paris; Kenrad E Nelson Journal: AIDS Res Hum Retroviruses Date: 2015-09-18 Impact factor: 2.205